Navigation Links
Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
Date:8/28/2008

OSLO, August 28 /PRNewswire-FirstCall/ --

- Results Further Support the Clinical Profile of This Novel Anti-Cancer Agent Under Development to Improve the Survival of Patients With Hormone Refractory Prostate Cancer (HRPC)

Algeta ASA (OSE: ALGETA), the Norwegian cancer therapeutics company, today announced that the primary objective of its BC1-03 Phase II pain palliation study was met. The study showed that even single doses of Alpharadin in patients with painful bone metastases could produce increasing clinical benefit with increasing dose. Pain palliation is an important quality of life benefit in metastatic cancer patients. The trial also confirmed Alpharadin's benign side-effect profile and, importantly for a drug in this clinical setting, no significant bone marrow toxicity was observed.

In men with HRPC life expectancy can be as short as 18 months, and it is estimated that 100,000 men in the EU and USA die from the disease each year. In 85% of these men the tumor will have spread into the bones. These metastases are a significant problem as they can cause intractable and debilitating pain as well as contributing to a further reduction in life expectancy.

The BC1-03 study was a double-blind randomised pain control study comparing the palliative effects of four different single dose levels of Alpharadin in patients with bony metastatic HRPC. The drug was given by i.v. injection mainly on an outpatient basis. The palliative efficacy of Alpharadin was measured using an assessment of bone pain as well as the patient's consumption of analgesia. The primary study objective was to investigate whether there was a dose-response relationship with respect to pain palliation in this patient group. The study has shown the beneficial palliative effect of a single dose of Alpharadin and that there is a clear dose-response effect, with higher doses providing better pain relief.

The study also showed a dose-dependent reduction in bone al
'/>"/>

SOURCE Algeta
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
2. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
3. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
4. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
5. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
6. Pharmasset Reports Preliminary Results of a 4-week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
7. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
8. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
9. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
10. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  GlySens Incorporated announced today that it ... from the National Institute of Diabetes and Digestive and ... of Health (NIH).  The grant is intended to support ... long term implantable glucose monitoring system.  Final preparations for ... expected to begin before the end of 2014. ...
(Date:11/23/2014)... Calif. , Nov. 23, 2014 Anthera ... that Paul F. Truex , President and Chief ... 2014 Annual Piper Jaffray Healthcare Conference. ... , at the Palace Hotel in New ... Pharmaceuticals Anthera Pharmaceuticals is a biopharmaceutical company ...
(Date:11/22/2014)... , 21 de noviembre de 2014 /PRNewswire/ ... ensayos clínicos externalizados y tecnologías eClinical, ha indicado ... de ,seguimiento inteligente, para el seguimiento basado en ... inteligente amplía el concepto del seguimiento basado en ... de las visitas de seguimiento o cambio de ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... April 12, 2011 Zimmer Holdings, Inc. (NYSE: ... sales and earnings conference call will be broadcast live over ... Eastern Time.  A news release detailing the quarterly results will ... of the conference call. The live audio ...
... /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (AMEX: ... a developer, manufacturer and distributor of botanical products, ... today announced that its wholly owned subsidiary, Harbin ... approval to produce water-based mixtures. The ...
Cached Medicine Technology:Zimmer Holdings Announces Live Audio Webcast and Conference Call of First Quarter 2011 Results 2China Botanic Pharmaceutical Approved to Produce Water-Based Mixtures 2China Botanic Pharmaceutical Approved to Produce Water-Based Mixtures 3
(Date:11/24/2014)... The Healthy Skin Care Journal, a ... skin care products, recently announced its launch. Located on ... wide variety of articles, tips, and evaluations about popular ... alternatives. , According to Emily Lataille, the website’s main ... thoroughly researched reviews, tips for the skin, and information ...
(Date:11/24/2014)... November 24, 2014 Volpara Solutions ... 1.2 at the 100th Annual Meeting of the ... 5, 2014 (RSNA Booth 1752 – South Hall). ... VolparaAnalytics and the rest of its innovative suite ... VolparaDoseRT, which enable personalized measurements of volumetric density, ...
(Date:11/24/2014)... UK (PRWEB) November 24, 2014 ... Massaggi , London's pre-eminent pain-relief service and massage ... Emmett Sports Massage (ESM). This newest sports ... , The key difference between traditional sports massage ... to access the body's very own "reset button,” ...
(Date:11/24/2014)... York (PRWEB) November 24, 2014 The ... by the Family and Children's Association to ... as soap, shampoo, mouthwash and other such items.The Association's ... who are home bound, living in nursing homes, assisted ... to greatly enhance the well being of seniors throughout ...
(Date:11/24/2014)... The typical American diet includes foods ... Consistently consuming a diet high in calories and carbohydrates ... fat that typically accumulate around the internal organs exposing ... head in the form of love handles, beer bellies ... decision to rid themselves of the burden of embarrassing, ...
Breaking Medicine News(10 mins):Health News:Skin Care Advice Blog The Healthy Skin Care Journal Now Accessible to the Public 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 2Health News:Sports Massage in London by Massaggi Presents New Technique to Reset Muscles, Rapidly Eliminate Pain 3Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 2Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 3Health News:Ketogenic Diet is the Perfect Solution for Diet Doc Patients Who Want to Learn How to Lose Weight over the Holidays 4
... Corporation,announced today that its reorganization agreement with several ... Under the terms of the proposed reorganization agreement ... private placement of common,shares for gross proceeds of ... within 14 days of the mailing of the ...
... could lead to more targeted prevention efforts, researcher says , , ... of choice for Hispanics in the United States, a new ... we can identify a type of beverage that is more ... policies can be developed to target that beverage and that ...
... the HiArt treatment system for advanced radiation therapy, announced today that ... manufacturer Chengdu Twin Peak Accelerator Technology Inc., based in Chengdu, China. ... ... 4, 2008 -- A linear accelerator (linac) is a key ...
... Conn., Nov. 4 VION,PHARMACEUTICALS, INC. (OTC Bulletin Board: ... Thursday, November 6, 2008 to,discuss its 2008 third quarter ... a.m. Eastern Time., To participate in the conference ... for international callers), at least 15 minutes,before the start ...
... new medication is,available to treat dogs with Cushing,s disease, ... managing the disease, according to a veterinarian,at Kansas State ... associate professor of clinical sciences, said a,new drug called ... but veterinarians may obtain the medication if they decide,it ...
... Proactive measures can reduce hip fracture rates by an average ... -- among those at risk, according to a study conducted ... on November 3 by The Journal of Bone & ... study of its kind, the five-year study tracked more than ...
Cached Medicine News:Health News:Study Shows Hispanics Prefer Beer 2Health News: TomoTherapy Completes Acquisition of Linear Accelerator Manufacturer in China 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:K-State Veterinarian Discusses Treating Dogs With Cushing's Disease 2Health News:Healthy bones program reduces hip fractures by 37 percent 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: